Novo Nordisk A/S Common Stock (NVO)

Revenue rose 49% year-over-year to nearly $600 million, while net income reached $15.8 million and adjusted EBITDA climbed 53% to $78.4 million.

Hims & Hers Health (NYSE: HIMS) became a significant after-hours mover on Monday, November 3, 2025, following the release of its third-quarter 2025 financial results and the pivotal announcement of renewed discussions with Novo Nordisk A/S (NYSE: NVO) regarding the potential distribution of Wegovy. While the telehealth platform reported a

Hims & Hers Health said late Monday it's in discussions with Novo Nordisk to sell Wegovy shots. The news buoyed Hims stock.

Here's a look at the Q3 earnings report from Hims & Hers Health.

These two leading drugmakers are fighting over a promising GLP-1 candidate.

Metsera called Pfizer's claims "nonsense" in a follow-up Monday to Pfizer's lawsuit against Metsera and Novo Nordisk.

Pfizer sues Metsera and Novo Nordisk, alleging breach of contract and antitrust violations over a rival $9 billion bid challenging its $4.9 billion merger deal.

It would be best to get in before the rest of the market pounces on these opportunities.

Novo Nordisk (NVO) is a top dividend stock with a 3.6% yield, strong growth, and a sustainable payout backed by exceptional profitability and financial health.

Viking's stock surged in one trading session after a positive clinical trial report last year.

Pfizer stock has dropped 50% over the past three years.

The biopharmaceutical industry is undergoing an immediate and profound transformation, as Artificial Intelligence (AI) rapidly compresses timelines, drastically reduces costs, and significantly enhances the precision of drug development from initial discovery to commercial manufacturing. This fundamental shift is giving rise to the "TechBio" era, where AI is no longer merely a supporting tool but the [...]

Pfizer sued Metsera and Novo Nordisk on Friday to prevent Novo's proposed $6.5 billion takeover of the smaller company.

Traders on Stocktwits linked Novo Nordisk’s renewed bid for Metsera to competition from Viking’s obesity drug VK2735, fueling further optimism.

As Eli Lilly, Novo Nordisk, and Pfizer battle for dominance in the obesity-drug market, these ETFs are offering exposure to the GLP-1 gold rush.

Novo Nordisk kicked off a battle with Pfizer on Thursday, making an unsolicited $6.5 billion bid for obesity-focused Metsera.

Novo Nordisk's $9 billion offer for Metsera challenges Pfizer's existing merger deal, prompting sharp criticism and potential legal action.

It offers compelling weight-loss drugs -- and a compelling stock price, too.

It's not the end of the world for the drugmaker.

These two have been neglected by Wall Street too much.